Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Mometasone furoate
Organon Pharma (Ireland) Limited
D07AC13
Mometasone furoate
0.1 percent weight/weight
Cream
mometasone
Marketed
1993-12-20
ELOCON® Cream mometasone furoate PACKAGE LEAFLET: INFORMATION FOR THE USER READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. • Keep this lea fl et. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What ELOCON is and what it is used for 2. Before you use ELOCON 3. How to use ELOCON 4. Possible side effects 5. How to store ELOCON 6. Further information 1. WHAT ELOCON IS AND WHAT IT IS USED FOR ELOCON Cream is one of a group of medicines called topical corticosteroids. It is classified as a “potent corticosteroid”. These medicines are put on the surface of the skin to reduce the redness and itchiness caused by certain skin problems. In adults and children, ELOCON Cream is used to reduce redness and itchiness caused by certain skin problems called psoriasis or dermatitis. Psoriasis is a skin disease in which itchy, scaly, pink patches develop on the elbows, knees, scalp and other parts of the body. Dermatitis is a condition brought on by the skin reacting to outside agents e.g. detergents, causing the skin to become red and itchy. 2. BEFORE YOU USE ELOCON DO NOT USE ELOCON • if you are allergic (hypersensitive) to mometasone furoate, any of the other ingredients of ELOCON, or to other similar medicines. • if you are allergic to soya. Elocon Cream may contain trace amounts of soya. • on any other skin problems as it could make them worse especially rosacea (a skin condition affecting the face), acne, skin atrophy (thinning of the skin), dermatitis around the mouth, genital itching, nappy rash, cold sores, chickenpox, shingles, ulcerated skin, wounds or other skin infections and widespread plaque psoriasis. Ask your doctor or pharma Read the complete document
Health Products Regulatory Authority 01 October 2021 CRN00C80D Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Elocon 0.1% w/w Cream 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mometasone Furoate 0.1% w/w (equivalent to 1.0 mg/g) Elocon cream contains hydrogenated soya phosphatidylcholine (15mg/g). For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Cream White to off-white smooth homogenous cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Elocon Cream is indicated for the topical management of corticosteroid responsive dermatoses. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults, including elderly patients and Children: _A thin film should be applied to the affected areas of skin once daily. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Safe use in children for more than 6 weeks has not been established. There are limited data in children under 2 years. 4.3 CONTRAINDICATIONS Use in acne vulgaris, rosacea, skin atrophy, perioral dermatoses or in widespread plaque psoriasis. Use in the presence of untreated infections of bacterial (e.g. impetigo, pyodermas), viral (e.g. herpes simplex, herpes zoster, chickenpox, verrucae vulgares, condylomata acuminata, molluscum contagiosum), tuberculous or parasitical and fungal origin (e.g. candida or dermatophyte) varicella, syphilis or post-vaccinal reactions. Dermatoses in children under one year of age, including dermatitis and napkin eruptions. Hypersensitivity to the preparation. Elocon should not be used on wounds or on skin which is ulcerated. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Local and systemictoxicity, includingsuppression of adrenocortical function mayoccur especiallyfollowingprolonged continueduse on large areas, in flexures andwith occlusion (includingnapkin). Chronic corticosteroid therapymayinterferewith thegrowth and development of children. Health Products Regulatory Authority 01 October 2021 CRN00C80D Page 2 o Read the complete document